Tonydarien Posted - 2 days ago

$OVID This is definitely a tax loss selling. There is a 30 day rule to buy back the stock after a loss. There is enough time for investors to buy back at the beginning of December without being penalized. “The "30-day rule" in stock trading refers to the "wash sale rule," which states that if you sell a security at a loss and then buy a substantially identical security within 30 days before or after the sale, you cannot claim that loss on your taxes; essentially, the sale is considered a "wash" and the loss is disregarded by the IRS.”

FORMER Posted - 3 days ago

$OVID On 9/9 Institutional Shares were 40,420,616 - 56.95% and today (11/18) Institutional Shares are now 43,221,006 - 60.87% 🤙

Vamanedu Posted - 1 week ago

$BYSI $OVID 🚨💥🚀🔥 PR is incoming. $BOLT.CN $.31 (+19.23%) average volume increased ~100%. I'm going to add on Monday if it's still this low. Latest News 🚀🤑 Market cap at $5.7M; Whiting’s influence may drive upward movement if new partnerships or exploration progress 1️⃣ Bolt Metals ($BOLT.CN) advances with two key updates: Ben Whiting joins as Technical Advisor, and a C$544,500 private placement closed 💸. 2️⃣ Funding: The placement includes shares and warrants, exercisable at C$0.75 for two years, with proceeds for exploration, working capital, and copper project growth ⚒️

Tonydarien Posted - 1 week ago

$OVID They continue to take one step forward and two steps backwards. They continue to crap on the shareholders. When will we start to see a return on our investment or are they just playing a shell game?

Skeetz99 Posted - 1 week ago

$OVID It’s been almost 6 months since these Takeda led studies finished. We weren’t given any feedback guidance in the earning release. See below. Soticlestat is currently in phase 3 clinical trials for treating seizures in Dravet syndrome, but the drug narrowly missed its primary endpoint in a recent study: Phase 3 results: In the SKYLINE study, soticlestat narrowly missed its primary endpoint of reducing the frequency of convulsive seizures in Dravet syndrome patients. However, the drug showed clinically meaningful effects in other key secondary endpoints. Soticlestat also showed a favorable safety and tolerability profile in the study. Next steps: Takeda will discuss the data with regulatory authorities.

Troopers Posted - 1 week ago

$OVID OV329 has been saving their ass times and times again. When will they learn? They need to move ahead full steam with OV329. It will make them a lot of money! Its mechanism of action has already been proven.

Skeetz99 Posted - 1 week ago

$OVID l Need a new CEO; it’s been years of gross underperformance in this sector .

Orrrrrrrrrrrrr Posted - 1 week ago

$OVID way down! :(

_intheshadows Posted - 1 week ago

$OVID

Tonydarien Posted - 1 week ago

$OVID From earnings report. Not good for stock price! “OV888/GV101 Capsule for CCM: Following the recent completion of long-duration competitor trials in CCM, and after discussions with key stakeholders, Ovid and Graviton Bioscience have decided to pause the initiation of the Phase 2 proof-of-concept study of OV888/GV101 capsule in CCM. Ovid and Graviton Bioscience received regulatory clearance to initiate a Phase 2 program in Israel and were in the process of applying for clearance in other regions, but they will take a strategic pause to evaluate clinical design learnings emerging from competitor Phase 2 programs. The companies are confident in the potential therapeutic effects of ROCK2 inhibition for CCM and will seek to optimize future development approaches with the benefit of further insights on study duration, enrichment strategies, endpoints, and time-to-event measurements.”

Orrrrrrrrrrrrr Posted - 1 week ago

$OVID what is the reason for this updise?

lucabrix Posted - 1 week ago

$OVID Way to run!

_intheshadows Posted - 1 week ago

$OVID

biolevity Posted - 1 week ago

$OVID moving this AM. KOL call this week

_intheshadows Posted - 2 weeks ago

$OVID news incoming?

lucabrix Posted - 2 weeks ago

$OVID Way to go UP!

_intheshadows Posted - 2 weeks ago

$OVID

Big_Zack22 Posted - 2 weeks ago

$OVID this will explode soon

Tonydarien Posted - 2 weeks ago

$OVID No mention of discussions with FDA about Takeda/Ovid Phase 3 status. https://www.businesswire.com/news/home/20241030235134/en/Takeda-Announces-Strong-First-Half-FY2024-Results-and-Raises-Full-Year-Outlook

Big_Zack22 Posted - 10/31/24

$OVID Good science here, no reason to worry.

Tonydarien Posted - 10/25/24

$OVID Has anyone heard Takeda’s progress in this area? Takeda will engage with regulatory authorities to discuss the totality of the data generated by these studies to determine next steps. Takeda will also plan to present results of both Phase 3 studies in DS and LGS at an upcoming scientific congress. See below to learn more about these syndromes. Here is Takeda’s Investor Relations email: [email protected]

perchedcats Posted - 10/24/24

$OVID adding here market cap is just too low and many catalysts on the horizon

Big_Zack22 Posted - 1 month ago

$OVID feeling really and strongly bullish here.

_intheshadows Posted - 1 month ago

$OVID

FlashMcGash Posted - 1 month ago

@_intheshadows I don't think that is accurate. Google soticlestat fda appoval for more info. I think there are other elements supporting and moving $OVID stock price, aside from soticlestat.

FlashMcGash Posted - 1 month ago

$OVID breaking out of current range? Its looking good.

DARKP00L Posted - 1 month ago

$OVID this stock is attracting a lot of interest. Be prepared for possible changes!

Skeetz99 Posted - 1 month ago

$OVID Company website indicates Soticlesat is Approved for Dravet Syndrome. Ovid would receive significant financial milestone payments from Takeda if this reality is true. Can anybody else confirm on their end?

_intheshadows Posted - 1 month ago

$DRUG adding $ANTF to the watchlist with $WOLF $HOOK $VS $OVID. Incredible movements over the past couple of days. $HOOK and $OVID are primed to move quick with volume.

_intheshadows Posted - 1 month ago

$DRUG watching $WOLF $HOOK $OVID $VS